Literature DB >> 9801038

Nd:YAG laser photodisruption for preretinal hemorrhage due to retinal macroaneurysm.

H Iijima1, S Satoh, S Tsukahara.   

Abstract

PURPOSE: To document the clinical course of Nd:YAG laser photodisruption for eyes with preretinal hemorrhage following rupture of a retinal macroaneurysm.
METHODS: We reviewed six eyes of five patients with preretinal hemorrhage due to retinal macroaneurysm that received Nd:YAG laser photodisruption. Nd:YAG laser created a focal opening in the anterior surface of the preretinal hemorrhage, permitting the blood to enter the vitreous cavity where it would be absorbed more rapidly.
RESULTS: Three eyes showed both subhyaloid hemorrhage, which was resorbed without treatment within 2 months, and hemorrhagic detachment of the internal limiting membrane (ILM), which required Nd:YAG laser photodisruption. All eyes showed disappearance of the preretinal hemorrhage and improvement of vision within 1 week of Nd:YAG laser photodisruption. Visual recovery was less prominent in eyes associated with subretinal macular hemorrhage.
CONCLUSION: Preretinal hemorrhage due to a ruptured retinal macroaneurysm could be dispersed into the vitreous cavity with Nd:YAG laser photodisruption. It should be considered in the decision of Nd:YAG laser photodisruption that the visual increment may be limited in eyes that also have subretinal hemorrhage in the macula and that the hemorrhage beneath the ILM tends to remain longer than the subhyaloid hemorrhage.

Entities:  

Mesh:

Year:  1998        PMID: 9801038     DOI: 10.1097/00006982-199805000-00008

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  Sub-inner limiting membrane haemorrhage: causes and treatment with vitrectomy.

Authors:  Karolien De Maeyer; Rita Van Ginderdeuren; Laurence Postelmans; Peter Stalmans; Joachim Van Calster
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

2.  Subhyaloidal and macular haemorrhage: localisation and treatment strategies.

Authors:  Stefan Mennel
Journal:  Br J Ophthalmol       Date:  2007-07       Impact factor: 4.638

3.  Nd:YAG membranotomy for preretinal hemorrhage secondary to valsalva retinopathy.

Authors:  Oscar Kuruvilla; Metasebia Munie; Manthan Shah; Uday Desai; Joel A Miller; Michael D Ober
Journal:  Saudi J Ophthalmol       Date:  2014-02-28

4.  [Spontaneous macula hemorrhage. Subhyaloid/sub-inner limiting membrane (ILM)].

Authors:  D Völcker; B Junker; L L Hansen
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

5.  Visual outcome after vitreous, sub-internal limiting membrane, and/or submacular hemorrhage removal associated with ruptured retinal arterial macroaneurysms.

Authors:  Hideo Nakamura; Kazuhisa Hayakawa; Shoichi Sawaguchi; Takeshi Gaja; Noriyoshi Nagamine; Kodo Medoruma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

6.  Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.

Authors:  Elsbeth J T van Zeeburg; Matteo G Cereda; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-04       Impact factor: 3.117

7.  Successful Resolution of Preretinal Haemorrhage with Intravitreal Ranibizumab.

Authors:  Baharuddin Noorlaila; Embong Zunaina; Mohd-Noor Raja-Azmi
Journal:  Case Rep Ophthalmol Med       Date:  2016-10-09

8.  Nd:YAG Laser Hyaloidotomy for the Treatment of Acute Subhyaloid Hemorrhage: A Comparison of Two Cases.

Authors:  Jens Heichel; Elisabeth Kuehn; Astrid Eichhorst; Thomas Hammer; Iris Winter
Journal:  Ophthalmol Ther       Date:  2015-12-22

9.  Retinal Arterial Macroaneurysms: Updating your Memory on RAM Management.

Authors:  Brian Evan Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2019-04-16

10.  Evaluation of pulsed Nd:YAG laser posterior hyaloidotomy as an emergency treatment for blinding premacular subhyaloid hemorrhage.

Authors:  Hazem A Hazem; Tarek A Shazly
Journal:  Open Access Emerg Med       Date:  2011-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.